Supply Chain Research

The U.S. continues to experience falling pharmaceutical prices. That’s being driven in part by the uncertainty about the future of healthcare reform as well as a push by the FDA to approve generic versions of branded drugs more quickly. The effect of generics can be seen in average import values per kilogram which have fallen 21% in the three months to August 31 on a year earlier. Oncology treatments – the largest class, saw a price decline of 7% while nervous-system treatments slumped 44%. Disruptions at Puerto Rican factories may require more international suppliers after a 16% rise in...